Target intelligence / Profile preview

SARS-CoV-2 spike glycoprotein (S protein)

Target
S protein
Molecular classification
Viral surface protein, Class I fusion protein, Glycoprotein
01

Overview

The SARS-CoV-2 spike glycoprotein is a large, trimeric class I fusion protein that decorates the surface of the SARS-CoV-2 virion, giving the virus its characteristic crown-like appearance [UniProt P0DTC2]. It is the primary mediator of viral entry into host cells, consisting of two functional subunits: S1, which contains the receptor-binding domain (RBD) for attachment to angiotensin-converting enzyme 2 (ACE2), and S2, which facilitates the fusion of viral and host cell membranes [Nature, 2020, 583, 7814]. Because of its essential role in the viral life cycle and its accessibility on the viral surface, the spike protein is the principal target for neutralizing antibodies induced by infection or vaccination [NIH, 2021]. Therapeutic interventions, including monoclonal antibodies like Sotrovimab and Bebtelovimab, specifically target epitopes on the spike protein to block ACE2 binding or inhibit the structural transitions required for fusion [FDA, 2022]. However, the protein is subject to significant evolutionary pressure, leading to mutations that can result in immune escape and reduced efficacy of existing therapeutics [PubMed, 34914510].

Other names
Spike proteinSurface glycoproteinS antigenSARS-CoV-2 S protein
02

Mechanism of action

Neutralization of viral entry by blocking the interaction between the receptor-binding domain (RBD) and the host ACE2 receptor, or by inhibiting the conformational changes required for membrane fusion.

03

Biological functions

Viral entryReceptor bindingMembrane fusionImmune evasion
04

Disease associations

InfectionCOVID-19
05

Safety considerations

Viral mutational escapeAntibody-dependent enhancement (ADE)Vaccine-induced immune thrombotic thrombocytopenia (VITT)Myocarditis
06

Interacting drugs

8 more in the full profile.

07

Biomarkers

Anti-spike IgG antibody titerNeutralizing antibody titerSpike protein antigen levels

Beyond the preview

Go deeper on SARS-CoV-2 spike glycoprotein (S protein).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SARS-CoV-2 spike glycoprotein (S protein).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call